Your provider adjusts your dose over time based on your tolerance, side effects, and weight loss progress
1 READ MORE: GLP-1 Agonists Associated with Doubled Risk of Neovascular AMD, Study Finds NAION moves the discussion beyond the retina A 2024 matched cohort study reporting increased NAION incidence among semaglutide-prescribed patients drew wide attention across ophthalmology, prompting debate over whether the association reflects a true optic nerve safety signal or the underlying vascular risk profiles of diabetic and obese populations
GLP-1s help the kidneys release more sodium into the urine, which reduces fluid buildup in the bloodstream and eases pressure on blood vessels
This significant difference highlights semaglutides potential as an effective tool in long-term weight management
Understanding and conveying too that generally these medications are meant for long term use and that they are complemented by a broader weight management plan may also help to change your reluctant physicians mind
5 Conclusions The use of SGLT-2 inhibitors and GLP-1 RAs in patients with cardiovascular risk has been well-established over the past decade